There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Although previous clinical study revealed that bortezomib combined with dexamethasone
had improved the outcomes of relapsed or refractory multiple myeloma (RRMM), the optimal
dose combinations of bortezomib and dexamethasone remain unknown. This trial aimed
to observe the efficacy and safety of different dose combinations of bortezomib and
dexamethasone in the treatment of RRMM patients in China.